Key facts
- This page summarizes David Baxley Spetzler's Form 4 filing for Caris Life Sciences, Inc. (CAI).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Sep 2026, 16:59.
David Baxley Spetzler - 03 Sep 2026 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)
- Reporting relationship
- President
- Issuer ticker
- CAI
- Reported as of
- 03 Sep 2026
- Net transaction value
- -$14,834,107
- SEC form
- 4
- Accepted by SEC
- 04 Sep 2026, 16:59:59 UTC
- Prior SEC filing
- 18 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Russel Denton, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Baxley Spetzler filed Form 4 for Caris Life Sciences, Inc. (CAI) on 04 Sep 2026.
Change
- Previous filing in this sequence was filed on 18 May 2026.
- Current net transaction value: -$14,834,107.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002071953
Primary reporting owner
Spetzler David Baxley
- Relationship
- President
- Address
- C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
- Signature
- /s/ J. Russel Denton, Attorney-in-Fact
- Signature date
- 04 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CAI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,000,000
- Change %
- +189%
- Price
- $2.44*
- Shares after
- 1,530,083
- Date
- 03 Sep 2026
- Ownership
- Direct
CAI
transaction
Common Stock
Sale
- Transaction value
- $9,733,313
- Shares
- -393,100
- Change %
- -26%
- Price
- $24.76
- Shares after
- 1,136,983
- Date
- 03 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F2
CAI
transaction
Common Stock
Sale
- Transaction value
- $2,149,676
- Shares
- -84,900
- Change %
- -7.5%
- Price
- $25.32
- Shares after
- 1,052,083
- Date
- 03 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F3
CAI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +250,000
- Change %
- +24%
- Price
- $2.44*
- Shares after
- 1,302,083
- Date
- 04 Sep 2026
- Ownership
- Direct
CAI
transaction
Common Stock
Sale
- Transaction value
- $2,951,117
- Shares
- -119,212
- Change %
- -9.2%
- Price
- $24.76
- Shares after
- 1,182,871
- Date
- 04 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CAI
transaction
Derivative
Stock Option
Options Exercise
- Transaction value
- Shares
- -1,000,000
- Change %
- -80%
- Price
- $0.000000*
- Shares after
- 250,000
- Date
- 03 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $2.44
- Footnotes
- F5, F6
CAI
transaction
Derivative
Stock Option
Options Exercise
- Transaction value
- Shares
- -250,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $2.44
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F5
Exercise of stock options before their expiration date.
Footnote F6
The stock option is fully vested and exercisable.
SEC remarks
President